We are live on ! Find out more
ANVS icon

Annovis Bio
ANVS

22 hedge funds and large institutions have $9.6M invested in Annovis Bio in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.27% less ownership

Funds ownership: 9.04% → 8.78% (-0.27%)

4% less capital invested

Capital invested by funds: $10M → $9.6M (-$441K)

12% less funds holding

Funds holding: 25 → 22 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
22
Holders Change
-3
Holders Change %
-12%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RAM
Redmond Asset Management
Virginia
+$425K
2
MFG
Merit Financial Group
Georgia
+$289K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$15.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.38K
5
Osaic Holdings
Osaic Holdings
Arizona
+$1.07K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$516K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$162K
3
KCM
Knoll Capital Management
Florida
-$147K
4
Morgan Stanley
Morgan Stanley
New York
-$145K
5
Bank of America
Bank of America
North Carolina
-$11.5K

ANVS Hedge Fund Activity: Q4 2022 in Review

22 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q4 2022, worth a combined $9.6M — down 4.4% from $10M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ANVS and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.

The largest buyer was Redmond Asset Management, opening a new position worth an estimated $425K. The largest seller was BlackRock, cutting an estimated $516K.

  • 22 institutional investors held Annovis Bio (ANVS) as of Q4 2022, down from 25 in Q3 2022.
  • Funds reported $9.6M of Annovis Bio stock for Q4 2022, down 4.4% quarter-over-quarter.
  • 1 fund opened new Annovis Bio positions in Q4 2022 and 4 closed out, a net change of -3 holders.
  • The largest Annovis Bio buyer in Q4 2022 was Redmond Asset Management, an estimated $425K added.
  • The largest Annovis Bio seller in Q4 2022 was BlackRock, an estimated $516K sold.

Based on aggregated 13F filings for Q4 2022.